←Back to Expert Scholars
Translational Medicine / 转化医学Cancer RNA Therapeutics, siRNA
Akin Akinc
PhD
🏢Aera Therapeutics🌐USA
Chief Executive Officer
45
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Akin Akinc led program development at Alnylam Pharmaceuticals and helped translate patisiran, the first siRNA drug approved by the FDA. He is a leader in LNP and GalNAc delivery systems for RNA therapeutics. He is now CEO of Aera Therapeutics, advancing new RNA delivery technologies with cancer applications.
Share:
🧪Research Fields 研究领域
lipid nanoparticle delivery
siRNA therapeutics
patisiran
RNA therapeutics translation
cancer RNA delivery
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Akin Akinc 的研究动态
Follow Akin Akinc's research updates
留下邮箱，当我们发布与 Akin Akinc（Aera Therapeutics）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment